PBLS compared with TYRA: revenue, margins and what each company keeps, and the suppliers and customers both name

PBLSParabilis Medicines, Inc.

Mkt capRevenueRevenue

TYRATyra Biosciences, Inc.

Mkt capRevenueRevenue

Compare

PBLSParabilis Medicines, Inc.

TYRATyra Biosciences, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

PBLS1 of 4 reports

Reportimpliedrealized× implied

Q2 FY26—▼−4.65%—

TYRA

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±26.7%▼−20.97%×0.79

May 13 '26±12.3%▲+3.79%×0.31

= impliedPBLS realized, solidTYRA realized, hatchedOne scale, both sides: full bar = 27%× = |realized| ÷ impliedSource: market data

Q1 FY26

±18.0%

▲+1.51%

×0.08

Nov 6 '25±25.6%▼−3.64%×0.14

PBLSParabilis Medicines, Inc.

27.91▼−2.77%· post 28.32

Mkt cap$818.7MRevenue$148,000Q2 FY26

TYRATyra Biosciences, Inc.

21.08▼−1.86%· post 21.08

ClosedOct 30 '26

Mkt cap$1.3BRevenue—

Compare

ClosedOct 30 '26

PBLSParabilis Medicines, Inc.

TYRATyra Biosciences, Inc.

27.91▼−2.77%post 28.32

Price

21.08▼−1.86%post 21.08

$818.7M

Mkt cap

$1.3B

Q2 FY26$148,000

Revenue

—

PBLS27.91▼−2.77%vsTYRA21.08▼−1.86%ClosedOct 30 '26